Zelapar® (selegiline hydrochloride)
This section provides a summary of the drug information for Zelapar® (selegiline hydrochloride).
If you have any further questions about your PD medication, or other aspects of your PD treatment, you should discuss these with your doctor or other healthcare professional.
Zelapar® is an adjunctive therapy used in combination with levodopa (with a peripheral decarboxylase inhibitor) in the treatment of Parkinson's disease.
Zelapar® in combination with maximal levodopa therapy is indicated particularly in patients who experience fluctuations in their condition such as 'end-dose' type fluctuations, 'on-off' symptoms or other dyskinesias.
Zelapar® may be used alone in early Parkinson's disease for symptomatic relief and/or to delay the need for levodopa.
Zelapar® is contraindicated in patients with a known hypersensitivity to any formulation of selegiline or any of the inactive ingredients of Zelapar.
Product information downloads
The information on this pageprintout is a general summary of the Zelapar® medication product.
Please click on the links below to download more detailed information on the Zelapar® medication, its handling and use.
Links go to the electronic Medicines Compendium (eMC) website.
Further detailed information on the Zelapar® medication, its handling and use can be downloaded via the electronic Medicines Compendium (eMC) website (http://emc.medicines.org.uk/):
Patient Information Leaflets (PIL)
Summary of Product Characteristics (SPC)
Please note that SPCs are designed for healthcare professionals.
Zelapar® is a registered trademark of Valeant Pharmaceuticals North America or its related companies.